What are the investment opportunities in remote patient monitoring and connected health?

This blog post has been written by the person who has mapped the remote patient monitoring and connected health market in a clean and beautiful presentation

The remote patient monitoring and connected health market presents compelling investment opportunities across multiple sub-segments experiencing rapid growth driven by regulatory changes, technological advances, and shifting healthcare economics.

With wearable devices and telehealth platforms leading growth trajectories at 18-23% CAGR, this sector offers diverse entry points for both entrepreneurs and investors seeking exposure to the digital health transformation.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

What are the major sub-segments of the remote patient monitoring and connected health market, and which ones are currently experiencing the fastest growth?

The remote patient monitoring market divides into five primary sub-segments, with wearable devices and telehealth platforms leading growth at 18-23% CAGR through 2030.

Who are the most prominent startups and established companies in this space, and what specific problems are they solving or disruptions are they aiming for?

Leading startups focus on predictive analytics and integrated care delivery, while established players leverage existing healthcare relationships and device manufacturing capabilities.

Biofourmis leads startup funding with $463.6M raised, developing personalized analytics platforms that predict clinical deterioration before it occurs. Forward Health raised $325M to create intelligent care clinics combining physical locations with integrated RPM biometrics and predictive risk scoring. Huma secured $322.6M for its prevention-oriented platform aggregating biosensor data for proactive health management.

FIRE1 raised $202.1M specifically for implantable heart-failure monitoring devices, addressing the gap in continuous cardiac surveillance. Lark obtained $195.7M for AI-driven virtual coaching targeting chronic disease management through behavioral interventions and continuous monitoring integration.

Established companies like Philips focus on Virtual Care Management solutions with broad provider partnerships, while Omron Healthcare develops connected blood pressure monitors with integrated RPM services that eliminate smartphone dependencies. GE Healthcare partnered with AMC Health to offer joint solutions for home-based chronic and post-acute care, leveraging existing hospital relationships.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

Validic operates as a health IoT platform enabling integration of patient-generated data into EHRs, solving the critical interoperability challenge that prevents widespread RPM adoption. These companies address specific disruptions: reducing rehospitalizations through early intervention alerts, seamless care coordination between virtual and physical settings, and bridging the gap between consumer health devices and clinical workflows.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

Which companies or startups in this industry are currently open to outside investors, and what are the typical conditions or requirements to get involved?

Most RPM startups from seed to Series C stages remain open to outside investors, with typical requirements including proven traction metrics and regulatory compliance.

Venture rounds in RPM typically require companies to demonstrate annual recurring revenue exceeding $1M, strong clinical validation through pilot programs, and regulatory clarity such as FDA 510(k) clearance or CE Mark approval. Strategic corporate investors, particularly device OEMs and payers, focus on partnerships requiring interoperability standards compliance (FHIR) and documented pilot outcomes showing measurable improvements.

Investment requirements generally include traction with health systems or payers through at least three active contracts, demonstrated cost-savings of 10% or greater reduction in readmissions or emergency visits, and scalable SaaS or device distribution models that can reach significant patient populations. Due diligence focuses heavily on clinical evidence, with investors requiring peer-reviewed studies or real-world evidence demonstrating efficacy.

Entry points vary by investor type: angel investors can participate with $25K-$100K minimums in seed rounds, while institutional investors typically require $500K-$2M commitments for Series A and beyond. Strategic investors often seek partnerships rather than pure equity investments, offering distribution channels, regulatory expertise, or clinical validation resources in exchange for equity stakes or revenue-sharing agreements.

What have been the most significant fundraising rounds in remote patient monitoring and connected health in 2025, and who were the lead investors?

The largest 2025 fundraising rounds exceeded $200M each, though lead investor details remain largely undisclosed in public announcements.

These mega-rounds reflect investor confidence in RPM's scalability and market potential, with funding primarily directed toward companies demonstrating clinical efficacy and provider adoption. The reluctance to disclose lead investors suggests strategic corporate involvement, potentially indicating acquisition interest or partnership development rather than traditional venture capital funding.

Which specific technologies—such as wearables, AI diagnostics, or telehealth platforms—are gaining the most traction with patients, providers, and investors?

Wearables command the largest adoption across all stakeholder groups, while AI-driven diagnostics attract the highest investor interest due to their potential for clinical workflow transformation.

Wearable devices achieve the strongest patient engagement due to ease of use and continuous vital sign capture without disrupting daily routines. Consumer-grade devices like smartwatches and fitness trackers create pathway adoption for medical-grade monitoring, with patients already comfortable with the technology before clinical need arises.

AI-driven diagnostics integrated into RPM platforms enable early intervention and personalized care plans, reducing clinical burden on providers while improving patient outcomes. These systems achieve 85% or higher positive predictive value for clinical alerts, making them valuable for provider workflow integration. Predictive analytics platforms can identify deterioration patterns 24-48 hours before traditional monitoring would detect issues.

Telehealth platforms drive hybrid models combining virtual visits with continuous monitoring, addressing both patient convenience and provider efficiency needs. Reimbursement parity laws in multiple states have accelerated adoption, with providers achieving cost savings through reduced emergency visits and improved chronic disease management.

Multi-parameter monitoring hubs provide comprehensive health snapshots appealing to hospitals and home-care agencies seeking complete patient visibility. These systems capture ECG, SpO₂, blood pressure, and other vitals simultaneously, reducing device complexity while improving data quality for clinical decision-making.

What are the main regulatory or reimbursement trends in North America and Europe that could impact the success of an investment in this sector?

CMS expanded RPM reimbursement codes in 2024-2025 significantly boost North American market viability, while European CE Mark simplification pilots accelerate market entry despite stricter EU MDR requirements.

The U.S. Centers for Medicare & Medicaid Services introduced new CPT codes for RPM and Chronic Care Management, enabling providers to bill $30-100 per patient per month for qualifying services. These reimbursement expansions create sustainable revenue models for RPM providers and incentivize health system adoption through improved economics.

FDA guidance on Software as Medical Device (SaMD) provides clearer regulatory pathways for AI-integrated RPM platforms, reducing time-to-market and regulatory uncertainty for investors. The FDA's Digital Health Center of Excellence expedites review processes for qualifying digital health technologies, particularly those demonstrating clinical benefit.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

In Europe, the EU Medical Device Regulation (MDR) raises evidence thresholds requiring more extensive clinical data, potentially increasing development costs and timeline. However, CE Mark streamlining pilots in Germany and France demonstrate regulatory willingness to accelerate approval for proven technologies. National telehealth parity laws across European countries create reimbursement frameworks supporting RPM adoption, though coverage varies significantly by country and application.

If you need to-the-point data on this market, you can download our latest market pitch deck here

Which business models are showing the strongest traction: B2B (clinics, hospitals), B2C (consumers), insurance-based, or hybrid models?

B2B models dominate revenue generation through health system partnerships, while hybrid approaches combining B2B and B2C channels show the strongest overall growth potential.

B2B models achieve the highest revenue per customer through licensing agreements with health systems and payers, generating $30-100 per patient per month subscription fees plus integration costs. These models benefit from longer contract terms, typically 2-3 years, and lower customer acquisition costs through established procurement processes.

Insurance-based models leverage value-based care contracts with shared-savings arrangements, requiring 5% or greater readmission reduction for payout triggers. These partnerships provide sustainable revenue through risk-sharing agreements but require extensive clinical validation and outcomes tracking capabilities.

Hybrid models package consumer devices with provider dashboards, unlocking both retail margins (20-40% on proprietary sensors) and enterprise subscription revenue. This approach creates multiple revenue streams while building brand recognition across patient and provider segments simultaneously.

B2C models face challenges with direct-pay sustainability, though premium subscription tiers for advanced features show growing acceptance among engaged users. Consumer device sales provide immediate revenue but require ongoing software subscriptions to maintain profitability and customer engagement.

How do these companies generate revenue, and what are the most common monetization strategies across successful players?

Revenue generation combines device sales margins, software subscriptions, data analytics services, and professional implementation fees across different customer segments.

• Device Sales: Hardware margins of 20-40% on proprietary sensors and monitoring equipment, with higher margins on specialized medical-grade devices compared to consumer-oriented products
• Software Subscriptions: Tiered pricing from $10-50 per patient per month based on feature sets, with enterprise plans including advanced analytics, integration capabilities, and clinical decision support tools
• Data Analytics Services: Custom reporting and predictive analytics generate $50-200K annual contracts with health systems requiring specialized insights and population health management capabilities
• Professional Services: Implementation, training, and EHR integration services command one-time fees of $50-150K, providing immediate revenue while ensuring successful platform adoption
• Value-Based Contracts: Shared-savings arrangements with payers based on documented outcomes improvements, typically requiring 10% reduction in target metrics for payment triggers

Successful companies diversify across multiple revenue streams to reduce dependency on any single source while maximizing customer lifetime value through comprehensive service offerings.

What are the most important KPIs and success metrics investors should track when evaluating opportunities in this space?

Patient engagement rates and clinical outcome improvements serve as primary indicators of platform viability, while revenue metrics and contract conversion rates demonstrate business model sustainability.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

If you want to build or invest on this market, you can download our latest market pitch deck here

What are the biggest unmet needs or gaps in the market where new entrants could provide differentiated value?

Behavioral health integration represents the largest unmet need, with limited RPM solutions addressing mental health monitoring despite growing demand for comprehensive care approaches.

Elderly-friendly interfaces create significant opportunities for new entrants capable of developing simplified user experiences for non-tech-savvy seniors. Current RPM devices often require smartphone proficiency or complex setup procedures that exclude large portions of the target demographic, particularly patients over 75 who would benefit most from continuous monitoring.

Interoperability solutions addressing seamless data exchange across disparate EHRs and device ecosystems remain underdeveloped. Health systems using multiple vendors struggle with data integration, creating opportunities for platforms that can aggregate and normalize data from various sources into unified clinical workflows.

Value-based evidence generation represents another gap, with many RPM companies lacking robust longitudinal studies demonstrating outcomes and cost savings. New entrants focusing on clinical research integration and real-world evidence generation could differentiate through proven efficacy data supporting payer negotiations and provider adoption.

Specialized chronic disease applications beyond diabetes and cardiovascular monitoring offer expansion opportunities, particularly for respiratory diseases, mental health conditions, and post-surgical recovery monitoring where existing solutions remain limited or fragmented.

What macro trends—such as aging populations, healthcare cost pressures, or clinician shortages—are driving long-term demand in connected health?

Aging populations create fundamental demand drivers, with 20% of the global population exceeding 65 years by 2030, requiring scalable monitoring solutions for age-related chronic conditions.

Healthcare cost pressures intensify through hospital readmission costs exceeding $17 billion annually globally, driving payer interest in preventive monitoring technologies that can reduce expensive acute care episodes. Value-based care models shift provider incentives toward outcome-based reimbursement, favoring RPM solutions that demonstrate measurable cost savings and improved patient outcomes.

Clinician shortages project a global deficit of 10 million health workers by 2030, necessitating technology solutions that extend provider reach and improve care efficiency. RPM platforms enable single providers to monitor larger patient populations while focusing clinical attention on high-risk cases identified through predictive analytics.

Consumer technology adoption accelerates through smartphone ubiquity and wearable device familiarity, reducing barriers to RPM technology acceptance among patient populations. 5G network rollout enables real-time data transmission and advanced analytics capabilities previously limited by connectivity constraints.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

Regulatory support through expanded reimbursement coverage and streamlined approval processes creates favorable operating environments for RPM companies, while pandemic-driven telehealth adoption establishes patient and provider comfort with remote care delivery models.

What are the realistic expectations for growth, exits, or acquisition opportunities in this market between now and the end of 2026?

The RPM and connected health market projects growth to $75-90 billion by 2026 with CAGR of 18-23%, supporting 15-20 strategic acquisitions annually averaging $200-500M deal sizes.

IPO activity anticipates 3-5 public debuts per year among high-growth digital health firms that achieve $100M+ annual revenue with demonstrated profitability or clear path to profitability. Public market receptiveness depends on companies showing sustainable unit economics and defensible competitive positions through clinical efficacy or network effects.

M&A trends favor partnerships between life-science corporates and RPM innovators seeking to expand digital-care portfolios. Large healthcare companies acquire RPM capabilities to integrate with existing product lines, while technology companies seek healthcare expertise and regulatory knowledge through strategic acquisitions.

Exit valuations typically range 8-15x annual recurring revenue for profitable companies with strong growth trajectories, while pre-profitability companies with significant clinical validation may achieve 5-8x revenue multiples. Strategic acquisitions often command premium valuations when synergies enable accelerated market penetration or product integration opportunities.

Acquisition targets generally require annual revenue exceeding $25M with growth rates above 40% annually, established customer bases including major health systems or payers, and differentiated technology or clinical outcomes supporting competitive advantages in consolidating markets.

Conclusion

Sources

1. Future Market Insights - Remote Patient Monitoring Devices Market
2. Markets and Markets - Remote Patient Monitoring Market
3. Markets and Markets - Emerging Trends in Remote Patient Monitoring
4. Grand View Research - Remote Patient Monitoring Devices Market
5. Medixine - Remote Monitoring Surges to 76.7 Million Patients Worldwide
6. Grand View Research - Connected Health Wellness Devices Market
7. Medical Startups - Top Remote Patient Monitoring Startups
8. Straits Research - Remote Patient Monitoring Market